Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections

Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis. Blocking critical mediators of immunity may carry a risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Kammüller, Michael, Tsai, Tsen-Fang, Griffiths, Christopher EM, Kapoor, Nidhi, Kolattukudy, Pappachan E, Brees, Dominique, Chibout, Salah-Dine, Safi Jr, Jorge, Fox, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579471/
https://www.ncbi.nlm.nih.gov/pubmed/28868144
http://dx.doi.org/10.1038/cti.2017.34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579471/
https://www.ncbi.nlm.nih.gov/pubmed/28868144
http://dx.doi.org/10.1038/cti.2017.34

Ejemplares similares